Download MendeleyFragment-Based Discovery of 6-Arylindazole JAK Inhibitors.
Ritzen, A., Srensen, M.D., Dack, K.N., Greve, D.R., Jerre, A., Carnerup, M.A., Rytved, K.A., Bagger-Bahnsen, J.(2016) ACS Med Chem Lett 7: 641-646
- PubMed: 27326341
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00087
- Primary Citation of Related Structures:
5L3A - PubMed Abstract:
Janus kinase (JAK) inhibitors are emerging as novel and efficacious drugs for treating psoriasis and other inflammatory skin disorders, but their full potential is hampered by systemic side effects. To overcome this limitation, we set out to discover soft drug JAK inhibitors for topical use. A fragment screen yielded an indazole hit that was elaborated into a potent JAK inhibitor using structure-based design. Growing the fragment by installing a phenol moiety in the 6-position afforded a greatly improved potency. Fine-tuning the substituents on the phenol and sulfonamide moieties afforded a set of compounds with lead-like properties, but they were found to be phototoxic and unstable in the presence of light.
Organizational Affiliation:
Drug Design, In Vitro Biology, Skin PK and Early Safety, and Preformulation & Early Analytical Development, Global R&D, LEO Pharma A/S , Industriparken 55, DK-2750 Ballerup, Denmark.
